To include your compound in the COVID-19 Resource Center, submit it here.

Sumitomo's transdermal blonanserin meets in Phase III for schizophrenia

Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) reported top-line data from a double-blind, international Phase III trial in 580

Read the full 180 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE